Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Cholinergic Antagonists; Ipratropium; Oxitropium

Criteria

Inclusion Criteria:

• Patients of both genders older than 40 years, who suffer from moderate or severe Chronic Obstructive Pulmonary Disease

• Only patients who showed following diagnosis parameters were to be considered for inclusion

• FEV1 (Forced expiratory volume in 1 second) and FEV1/VC (vital capacity) <70%

• Reversibility FEV1 <12% in the last 6 months

• Smoker or Ex-smoker (>10 Pack years)

• Asthma to be excluded

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics